Storia in 3 fonti

A standing ovation for RevMed, and caution for Akeso

ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.

Raccontata dastatnews.comfiercebiotech.comfiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

fiercebiotech.com2 g fa

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this ye | This year’s meeting…

Leggi questa versione → originale

statnews.com2 g fa

Practice-changing results reported for Revolution Medicines pancreatic cancer drug

Revolution Medicines' daraxonrasib, a targeted oral therapy for pancreatic cancer, roughly doubled patient survival versus standard chemotherapy in a Phase trial presented at ASCO 2026 and published simultaneously in the New England Journal of Medicine. For biotech and oncology investors, this is the first meaningful efficacy signal in a notoriously treatment-resistant indication, likely to accelerate M&A interest and pipeline repositioning toward RAS-targeted agents.

Leggi questa versione → originale

fiercepharma.com2 g fa

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival…

Leggi questa versione → originale

Timeline cronologica

1. venerdì 29 maggio 2026·statnews.com
   

   At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

   You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions

2. sabato 30 maggio 2026·statnews.com
   

   BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

   ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.

3. sabato 30 maggio 2026·statnews.com
   

   BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA

   ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.

4. domenica 31 maggio 2026·fiercebiotech.com
   

   ASCO: Revolution Medicines confident in RAS leadership as rivals square up

   This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data…

5. domenica 31 maggio 2026·statnews.com
   

   Practice-changing results reported for Revolution Medicines pancreatic cancer drug

   Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.

6. domenica 31 maggio 2026·fiercepharma.com
   

   ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

   It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t…

7. lunedì 1 giugno 2026·statnews.com
   

   A standing ovation for RevMed, and caution for Akeso

   ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.

8. lunedì 1 giugno 2026·statnews.com
   

   A turning point for pancreatic cancer patients

   Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

9. lunedì 1 giugno 2026·statnews.com
   

   At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways

   Here is some of what you may have missed from the world's largest cancer research meeting.